Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.37
Nov 18 • 3:59 PM ET Dollar change-0.03 Percentage change(-2.14%)
Aftermarket Close
1.37
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
90.09M
Enterprise Value
98.04M
Income
-29.94M
Sales
0.00M
Book/sh
0.28
Cash/sh
0.03
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
22
IPO
Feb 22, 2013
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
4.82
P/C
47.67
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
0.47
Current Ratio
0.47
Debt/Eq
0.50
LT Debt/Eq
0.49
Option/Short
No / Yes
EPS (ttm)
-0.49
EPS next Y
-0.50
EPS next Q
-0.11
EPS this Y
22.54%
EPS next Y
-1.64%
EPS next 5Y
16.76%
EPS past 3/5Y
87.54% 81.38%
Sales past 3/5Y
- -
EPS Y/Y TTM
24.26%
Sales Y/Y TTM
-
EPS Q/Q
29.67%
Sales Q/Q
-
Insider Own
34.62%
Insider Trans
0.00%
Inst Own
10.39%
Inst Trans
3.71%
ROA
-96.64%
ROE
-167.53%
ROIC
-105.81%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-20.08%
SMA50
-26.93%
SMA200
-32.51%
Trades
Shs Outstand
65.76M
Shs Float
42.99M
52W High
3.43 -60.06%
52W Low
0.41 234.15%
Volatility
12.04% 11.00%
ATR (14)
0.16
RSI (14)
33.63
Beta
-0.17
Rel Volume
0.59
Avg Volume
326.59K
Volume
194,108
Perf Week
-9.87%
Perf Month
-22.16%
Perf Quarter
-38.29%
Perf Half Y
-42.68%
Perf YTD
81.05%
Perf Year
-29.02%
Perf 3Y
-89.30%
Perf 5Y
-99.90%
Perf 10Y
-100.00%
Prev Close
1.40
Price
1.37
Change %
-2.14%
Consensus
Strong Buy
Avg. Price Target
$7.87
Implied Upside
+474.5%
Analysts4incl. previous ratings
Rating Distribution4 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Apr 27, 2026Initiated
CCitizens
Mkt Outperform$9+556.9%
Mar 03, 2025Initiated
HH.C. Wainwright
Buy$13+848.9%
Dec 19, 2024Initiated
RRodman & Renshaw
Buy$11+702.9%
Nov 05, 2024Initiated
MMaxim Group
Buy$15+994.9%
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. Its lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded by Michael Lawman, Patricia Lawman and James A. Bianco on May 4, 2023 and is headquartered in Tampa, FL.
PresidentDr. James A. Bianco M.D.
Executive VP of Finance & CFOMr. Dan Dearborn CPA
Co-FounderMr. Michael Lawman
Co-FounderMs. Patricia Lawman
Head of Quality AssuranceMr. Michael Krsulich